(90 days)
Tactoset® Injectable Bone Substitute is a synthetic, biocompatible bone graft substitute material that hardens and converts to a poorly crystalline hydroxyapatite at body temperature. It is indicated for filling bone voids or defects of the skeletal system (i.e. extremities and pelvis) that are not intrinsic to the stability of bony structure. These defects may be surgically created osseous defects or defects created from traumatic injury to the bone. The device provides an injectable, self-setting, osteoconductive bone graft substitute that resorbs and is replaced by the growth of new bone during the healing process and may be combined with autogenous bone marrow. Tactoset® Injectable Bone Substitute can augment hardware and support bone fragments during the surgical procedure. The cured paste acts only as a temporary support media and is not intended to provide structural support during the healing process.
Tactoset is an injectable osteoconductive calcium phosphate bone graft substitute material. It is provided to the end-user as two components (a dry powder and an aqueous solution in separate pre-loaded syringes) that must be mixed intra-operatively prior to implantation using the supplied mixing system to form a cohesive paste. The dry powder component is composed of the alpha phase of tricalcium phosphate [Ca3(PO4)2], calcium carbonate [CaCO3], and monocalcium phosphate [Ca(H2PO4)2]. The liquid component is composed of sodium phosphate dibasic [Na2HPO4], citric acid [CaHgO7], hyaluronic acid (HA), and water for injection. At a specified volume, the aqueous setting solution can be combined with autogenous bone marrow, i.e., bone marrow aspirate. Tactoset is provided sterile for single use.
The provided text describes a 510(k) premarket notification for a medical device called Tactoset. It focuses on demonstrating substantial equivalence to predicate devices rather than providing specific acceptance criteria and detailed study results for the device itself. Therefore, many of the requested details about acceptance criteria, specific performance metrics, sample sizes, expert qualifications, and ground truth establishment are not present in the provided document.
However, based on the available information, I can extract what is present:
1. A table of acceptance criteria and the reported device performance
The document does not explicitly present acceptance criteria in a quantitative table with specific targets. Instead, it demonstrates "substantial equivalence" to predicate devices through various comparisons, including material composition, physical properties, mechanical testing, and an animal functional study. The closest an explicit performance comparison comes is in the animal study section:
| Performance Metric | Subject Device (Tactoset + BMA) Performance | Predicate Device (Tactoset) Performance | Negative Control (Empty Defect) Performance |
|---|---|---|---|
| New Bone Formation (at 12 weeks) | Averages 14.90% | Averages 14.65% | 5% |
| Implant Material Remaining (at 12 weeks) | Approximately 54.3% | Approximately 60.9% | N/A |
Other aspects like mixing time, working time, setting time, sterility, and pyrogenicity are presented as characteristics that are equivalent to the predicate device, implying that the predicate's performance in these areas serves as an "acceptance criteria" through analogy.
| Characteristic | Subject Device Performance | Primary Predicate Performance |
|---|---|---|
| Mixing Time (Min) | 1 | 1 |
| Min Working Time (Min) | 7-18 | 7-18 |
| Setting Time (Min) | 10 | 10 |
| Sterility Method | Single Use, Sterile, SAL 10-6 | Single Use, Sterile, SAL 10-6 |
| Pyrogenicity | LAL |
§ 888.3045 Resorbable calcium salt bone void filler device.
(a)
Identification. A resorbable calcium salt bone void filler device is a resorbable implant intended to fill bony voids or gaps of the extremities, spine, and pelvis that are caused by trauma or surgery and are not intrinsic to the stability of the bony structure.(b)
Classification. Class II (special controls). The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance: Resorbable Calcium Salt Bone Void Filler Device; Guidance for Industry and FDA.” See § 888.1(e) of this chapter for the availability of this guidance.